

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

24

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>C07K 14/47, 16/18, G01N 33/68</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/09058</b> <b>(43) International Publication Date:</b> 25 February 1999 (25.02.99)
<b>(21) International Application Number:</b> PCT/FI98/00550 <b>(22) International Filing Date:</b> 24 June 1998 (24.06.98)  <b>(30) Priority Data:</b> 973371 15 August 1997 (15.08.97) FI  <b>(71)(72) Applicants and Inventors:</b> HELLMAN, Jukka [FI/FI]; Amiraalistonkatu 5 C 12, FIN-20100 Turku (FI). KÄKÖNEN, Sanna-Maria [FI/FI]; Murtomaantie 39, FIN-20300 Turku (FI). KARP, Matti [FI/FI]; Kampakatu 1, FIN-20660 Littoinen (FI). LÖVGREN, Timo [FI/FI]; Yliopistonkatu 2 H 155, FIN-20100 Turku (FI). VÄÄNÄNEN, H., Kalervo [FI/FI]; Peikontie 2 D 43, FIN-90550 Oulu (FI). PETTERSSON, Kim [FI/FI]; Tiilentekijäncatu 14 E 20, FIN-20810 Turku (FI).  <b>(74) Agent:</b> TURUN PATENTTITOIMISTO OY; P.O. Box 99, FIN-20521 Turku (FI).		<b>(81) Designated States:</b> JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> ISOLATED OSTEOCALCIN FRAGMENTS		
<b>(57) Abstract</b> <p>The invention relates to an isolated osteocalcin fragment derived from human urine, said fragment being characterized in that at least one of the glutamic acids in the position 17, 21 and 24 of the amino acid sequence (I) is gamma-carboxylated. The invention concerns further a monoclonal antibody or recombinant antibody fragment capable to bind said fragment, a cell line producing said monoclonal antibody, and an immunoassay for quantitative determination of said fragment. Furthermore, the invention concerns a method for the measurement of the rate of bone turnover (formation and/or resorption) and/or for the investigation of metabolic bone disorders.</p> <div style="text-align: right; margin-right: 100px;">         6 7  <b>Tyr-Leu-Tyr-Gln-Trp-Leu-Gly-Ala-</b>  <b>Pro-Val-Pro-Tyr-Pro-Asp-Pro-Leu-</b>          17 21 24  <b>Glu-Pro-Arg-Arg-Glu-Val-Cys-Glu-Leu- (I)</b>          30  <b>Asn-Pro-Asp-Cys-Asp-Glu-Leu-Ala-</b>  <b>Asp-His-Ile-Gly-Phe-Gln-Glu-Ala-</b>  <b>Tyr-Arg-Arg-Phe-Tyr-Gly-Pro-Val</b> </div>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## ISOLATED OSTEOCALCIN FRAGMENTS

## FIELD OF THE INVENTION

5 This invention relates to an isolated osteocalcin fragment derived from human urine, a monoclonal antibody or recombinant antibody fragment capable to bind said fragment, a cell line producing said monoclonal antibody, and an immunoassay for quantitative determination of said fragment. Furthermore, the invention concerns a method for the measurement of the rate of bone turnover (formation and/or  
10 resorption) and/or for the investigation of metabolic bone disorders.

## INTRODUCTION AND BACKGROUND

15 The publication and other materials used herein to illuminate the background of the invention, and in particular, cases to provide additional details respecting the practice, are incorporated by reference.

Human osteocalcin (hOC), also designated bone Gla protein (BGP), is the most  
20 abundant noncollagenous protein synthesized by bone osteoblast (Poser et. al. J Biol Chem 1980; 255:8685-91). Although most of the synthesized osteocalcin is absorbed to bone hydroxyapatite by  $\gamma$ -carboxylated glutamic acids (Gla), a small part of it leaks into the blood stream where it can be detected (Price et al. J Biol Chem 1981; 256:12760-6). Part of the hOC found in blood is also thought to  
25 originate from the resorption process, when the hOC inside the bone tissues is released during bone degradation (Gundberg and Weinstein J Clin Invest 1986; 77:1762-7). Levels of circulating hOC have been widely used in the clinical investigations as a marker of bone formation (Power and Fottrell Crit Rev Clin Lab Sci 1991; 28:287-335) and serum hOC levels have been shown to correlate with

bone mineral density measurements (Yasamura et al. J Clin Endocrinol Metab 1987; 64:681-5).

The discordant results obtained from different hOC assays have hindered  
5 widespread usage of hOC in clinical applications (Masters et al. Clin Chem 1994; 40:358-63, Deftos et al. Clin Chem 1992; 38:2318-21, Delmas et al. J Bone Miner Res 1990; 5:5-11 and Diego et al. 1994; 40:2071-7). This phenomenon could partly be explained due to different assay formats i.e. sandwich vs. competitive assays or due to different detection techniques. Presently no calibration standard is available.  
10 However, even if the same standard preparation is used, hOC levels measured in different laboratories cannot be directly compared (Delmas et al. J Bone Miner Res 1990). The diversity of hOC molecule itself in circulation has an evident contribution to its immunoreactivity in various assays. The vitamin K dependent  $\gamma$ -carboxylation degree of the glutamic acid residue varies (Poser et. al. J Biol Chem  
15 1980; 255:8685-91). Impairment  $\gamma$ -carboxylation of hOC purified from bone has been indicated by Cairns and Price, J Bone Min Res 1994; 9:1989-97 and confirmed in our studies (Hellman et al. J Bone Miner Res 1996; 11:1165-75). When  $\text{Ca}^{2+}$  binds to Gla residues an  $\alpha$ -helix structure is known to form (Hauschka and Carr, Biochemistry 1982; 21:2538-47 and Atkinson et al. Eur J Biochem 1995; 232:515-  
20 21). Upon removal of  $\text{Ca}^{2+}$  with EDTA this helical conformation is destroyed. The conformation of decarboxylated OC lies somewhere between the random coil and helical form. Thus, in solution the peptide occurs as a flexible structure and a single conformation cannot be defined for it (Atkinson et al. Eur J Biochem 1995; 232:515-21). Peptide bonds between arginine residues 19 and 20 and between  
25 residues 43 and 44 are susceptible to tryptic hydrolysis leading to peptides 1-19, 20-43, 45-49, 1-43, and 20-49 which may be the main products of hOC breakdown in the circulation (Farrugia and Melick, Calcif Tissue Int 1986; 39:234-8, Hellman et al. J Bone Miner Res 1996; 11:1165-75 and Garnero et al. J Bone Miner Res 1994; 9:255-4).

Multiple immunoreactive forms of hOC have been discovered in circulation (Garnero et al. J Bone Miner Res 1994; 9:255-4) and also in urine (Taylor et al. J Clin Endocrin Metab. 1990; 70:467-72). The fragments of hOC can be produced either during osteoclastic degradation of bone matrix or as the result of the catabolic breakdown of the circulating protein after synthesis by osteoblasts. There is evidence that the production of some of the fragments found in urine occurs before renal clearance and is not a result of it (Taylor et al. J Clin Endocrin Metab. 1990; 70:467-72). Because of the rapid clearance from the circulation by glomerular filtration, the shOC (serum human OC) could reflect the acute changes in bone metabolism, while some of the uhOC (urine human OC) fragments might serve as an index of long term changes (Price et al. J Biol Chem 1980; 256:12760-6).

The first reported measurement of urine osteocalcin (Taylor et al. J Clin Endocrin Metab. 1990; 70:467 - 72) is based on competitive RIA utilizing polyclonal guinea pig antihuman OC antibodies for recognizing the immunoreactive OC fragments (Taylor et al. Metabolism 1988; 37:872-7.). The assay is said to be specific for the midmolecule epitope of hOC molecule according to information obtained from crossreactivity tests with tryptic fragments and synthetic peptide. The probable epitope for polyclonal antibody recognition is determined quite widely by the authors. It is concluded that the binding site of antisera is located in the midmolecule of the protein and probably involves amino acid 19 and at least a portion of the N-terminal sequence of the 20-43 tryptic digest fragment prior to amino acid 37. The assay is unable to distinguish decarboxylated hOC from carboxylated hOC in other words it is not dependent on the  $\gamma$ -carboxylation degree of glutamic acids 17, 21 and 24 in hOC. Furthermore the detailed characterization of the fragments detected by the assay is missing. In addition, this assay is not suitable for routine measurement of urine because the desalting of urine samples before measurement is inevitable for the proper function of RIA. Because of the

titer of immunoresponse to hOC varied remarkably with the individual animals, batch-to-batch variations in antibody production are likely to occur, which in term reduces the reproducibility of the assay. With this assay, in both serum and urine multiple immunoreactive OC-fragments have been detected. In addition, multiple  
5 fragments were found in normal adult urine that were not detected in normal adult serum. However, the observed immunoreactive fragments were not characterized in detail. uhOC is better able to distinguish between children with high bone turnover and normal adults than serum hOC. The correlation between the serum and the urine samples as measured by the uhOC RIA was good indicating that the assay is  
10 detecting osteocalcin originating from the formation process ( $r = 0.83$ ,  $p < 0.01$ ). Besides this, even better correlation was obtained between uhOC and serum alkaline phosphatase measurements. (Taylor et al. J Clin Endocrin Metab. 1990; 70:467-72). A disadvantage of using shOC as a bone metabolism marker is the obvious diurnal variation of hOC concentration (Gundberg et al. J Clin Endocrinol Metab 1985;  
15 60:736-9). One solution for the problem might be to determine the hOC values in 24-hour urine pool.

In the menopause the concentration of serum osteocalcin is increased. The level of increase is partly dependent on the differences in the osteocalcin assays employed  
20 or the population studied, but is generally about 30 -50 % above the premenopausal values (Ravn et al. Bone 1996; 19:291-8, Bonde et al. J Clin Endocrinol Metab 1995; 80:864-8, Garnero et al. J Bone Miner Res 1996; 11:337-49, Åkesson et al. J Bone Miner Res 1995; 1823-9). Generally, the concentration of hOC decreases during antiresorptive treatment like hormon replacement therapy (HRT) (Chen et al.  
25 J Bone Miner Res 1996; 11:1784-92, Hodsman et al. J Clin Invest 1993; 91:1138-48). Serum hOC measurements are therefore utilized for monitoring the effectiveness of treatment and also in the pharmaceutical studies designing new antiresorptive drugs. High turnover in bone metabolism in children and especially, in puberty increases the hOC concnetrations remarkably (Taylor et al. J Clin

Endocrin Metab. 1990; 70:467-72, Jaouhari et al. Clin Chem 1992; 38:1968-74, Gundberg et al. Clin Chim Acta 1983; 128:1-8).

## SUMMARY OF THE INVENTION

5

This invention relates to an isolated osteocalcin fragment derived from human urine, said fragment being characterized in that at least one of the glutamic acids in the position 17, 21 and 24 of the amino acid sequence

10

6 7  
Tyr-Leu-Tyr-Gln-Trp-Leu-Gly-Ala-

Pro-Val-Pro-Tyr-Pro-Asp-Pro-Leu-

15

17 21 24  
Glu-Pro-Arg-Arg-Glu-Val-Cys-Glu-Leu-

20

30  
Asn-Pro-Asp-Cys-Asp-Glu-Leu-Ala-

Asp-His-Ile-Gly-Phe-Gln-Glu-Ala-

Tyr-Arg-Arg-Phe-Tyr-Gly-Pro-Val

25 is gamma-carboxylated.

According to another aspect, the invention relates to a monoclonal antibody or recombinant antibody fragment having the capability of binding the human gamma-carboxylated osteocalcin fragment as defined above.

30

According to a third aspect, the invention concerns a cell line producing said monoclonal antibody.

According to a fourth aspect, the invention relates to an immunoassay for quantitative determination of a gamma-carboxylated osteocalcin fragment defined above, said immunoassay being characterized in that a sample containing said fragment is exposed to a monoclonal antibody or recombinant antibody fragment which binds said gamma-carboxylated osteocalcin fragment.

According to a fifth aspect, the invention relates to a method for the measurement of the rate of bone turnover (formation and/or resorption) and/or for the investigation of metabolic bone disorders in an individual, said method being based on the quantitative determination of an osteocalcin fragment as defined above.

This is the first report of isolation and characterization of osteocalcin fragments in urine. Three two-site assay detecting these hOC fragments in urine utilizing well characterized reagents are described and validated with clinical samples. The described non-competitive immunoassays are the first assays sensitive enough for the detection of urine osteocalcin fragments in routine clinical measurements. Urine hOC discriminates the pubertal subjects from the adult subjects better than the serum hOC. In addition, an outstanding clinical utility for the discrimination of the postmenopausal group from the premenopausal group is observed. Furthermore, hOC concentrations in postmenopausal group receiving antiresorptive treatment are significantly lower when compared to the concentrations in control postmenopausal group. Serum and urine samples from the same individuals do correlate using the same assay but substantial differences do occur. This result indicates that the fragments of hOC in urine might reflect different state of bone metabolism than fragments of hOC in serum.



## BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 A shows the nucleic acid and the amino acid sequences of the synthetic human osteocalcin insert. Figure 1 B shows plasmid vector pGEX-3X (Pharmacia).

- 5 The arrow indicates the SmaI-ligation site of the hOC insert. The pfxa (protease factor Xa) cleavage site is located after the Ile-Glu-Gly-Arg -sequence.

Figure 2 A shows SDS-PAGE and Figure 2 B shows Western blotting analysis of various osteocalcin forms. Lane 1. Low molecular weight (kDa) markers, lane 2.

- 10 Affinity-purified GST (glutathione S-transferase), lane 3. hOC purified from human bone, lane 4. bOC (bovine osteocalcin), lane 5. Affinity-purified GST-rhOC (GST-recombinant human osteocalcin fusion protein), lane 6. Chromatographically purified rhOC (recombinant human osteocalcin) i.e. the cleavage product from incubation of GST-rhOC with pfxa.

15

Figure 3 is a schematic representation of the approximate epitopes recognized by the Mabs used in two-site hOC assays. The molecule has been divided into four epitope areas each of which is being recognized by different Mabs. Circled numbers indicate the number of the hOC specific immunoassay. Amino- and carboxyterminal amino acids have been marked as 1 and 49, respectively. The protease-sensitive sites have been indicated as R-R (arginine-arginine), the three Gla-residues are shown as well as the disulphide bridge (C-C).

20

Figure 4 shows the determination of immunoreactive uhOC fragments in normal pubertal urine. Urine was subjected to immunoaffinity chromatography and solid phase extraction before HPLC fractionation. The fractions were measured for immunoreactive material with hOC specific assay #7. The squares refer to osteocalcin and the triangles to acetonitrile.

25

Figures 5 A to 5 E show characteristics of the immunoreactive hOC fragments isolated from normal pubertal urine. Fig. 5 A: Mass analysis of the most prominent fragment 44 isolated from urine spanning the amino acid residues 7-30 (Gly-Asp). Fig. 5 B: Mass analysis of the urine hOC fragment 46 spanning the amino acid residues 6-30 (Leu-Asp). Fig. 5 C: Mass analysis of the urine hOC fragment 43. Fig. 5 D: Mass analysis of the urine hOC fragment 47. Fig. 5 E: Characteristics of the hOC fragments isolated in urine and characteristics of intact hOC.

Figure 6 shows the difference between the hOC concentrations in serum and urine between pubertal and adult samples as measured by the hOC IFMAs. hOC concentration in urine and serum samples was clearly higher in pubertal girls than in premenopausal women as measured with the hOC immunoassays.

Figures 7 A and 7 B demonstrate hOC levels in pre-, postmenopausal and postmenopausal with HRT groups of women measured with the IFMAs. The concentrations have been obtained in serum (Fig. 7 A) and urine (Fig. 7 B) samples of adult females. In the urine samples the differences between menopausal groups were more obvious than in the serum samples even as measured with the same combination of Mabs.

Figures 8 A to 8 D show correlations between different assays measured in urine and serum samples from adult female panel. Fig. 8 A: Correlation between uhOC as measured by the assays #4 and #7. Fig. 8 B: Correlation between uhOC as measured by the assays #7 and #9. Fig. 8 C: Correlation between serum and urine samples as measured by the assay #7. Fig. 8 D: Correlation between serum and urine samples as measured by the assay #4.

## DETAILED DESCRIPTION OF THE INVENTION

According to a preferred embodiment, the isolated osteocalcin fragment derived from human urine is a fragment spanning i) from the amino acid in position 7 to the amino acid in position 30, or ii) from the amino acid in position 6 to the amino acid in position 30 of the amino acid sequence

10 Tyr-Leu-Tyr-Gln-Trp-Leu-Gly-Ala-  
Pro-Val-Pro-Tyr-Pro-Asp-Pro-Leu-  
15 17 21 24  
Glu-Pro-Arg-Arg-Glu-Val-Cys-Glu-Leu-  
Asn-Pro-Asp-Cys-Asp-Glu-Leu-Ala-  
20 Asp-His-Ile-Gly-Phe-Gln-Glu-Ala-  
Tyr-Arg-Arg-Phe-Tyr-Gly-Pro-Val

25 where all three glutamic acids in the positions 17, 21 and 24 of said sequence are gamma-carboxylated.

The preferred monoclonal antibody or recombinant antibody fragment has a specificity to epitopes that have been identified on the gamma-carboxylated  
30 fragment of osteocalcin, wherein said fragment spans either

- i) from the amino acid in position 7 to the amino acid in position 30, or  
ii) from the amino acid in position 6 to the amino acid in position 30  
of the amino acid sequence described above, and that all three glutamic acids in the  
positions 17, 21 and 24 of said sequence are gamma-carboxylated.

The preferred immunoassay according employs a monoclonal antibody or recombinant antibody fragment having the said specificity.

- 5 The preferred immunoassay is a non-competitive immunoassay employing at least two different monoclonal antibodies or recombinant antibody fragments.

The non-competitive immunoassay is preferably carried out in either a one-step or a two-step incubation procedure.

10

Particularly preferable immunoassays are those where the two monoclonal antibodies employed are

- i) the antibodies 2H9 and 6F9 that recognize the C-terminal and N-terminal epitopes  
15 on the fragment which was determined to be 3005.
- ii) the antibodies 6F9 and 1C4 that recognize the N-terminal and the C-terminal epitopes on the measured osteocalcin fragments (6-30 or 7-30), or
- 20 iii) the antibodies 6F9 and 3H8 that recognize the N-terminal and the C-terminal epitopes on the measured osteocalcin fragments (6-30 or 7-30).

All the disclosed assays are highly sensitive and are based on widely characterized reagents. Difference in hOC concentration between the premenopausal and the  
25 pubertal group was clearly higher in urine samples than in serum samples. All the hOC assays discriminated the menopausal groups effectively using either serum or urine specimens. Due to their ability to detect different hOC forms, these assays should be of interest in monitoring various disease states, particularly of bone metabolism diseases. The assays are thus especially useful in methods for the

measurement of the rate of bone turnover (formation and/or resorption) and/or for the investigation of metabolic bone disorders.

## 5 EXPERIMENTAL

### 1. Production of the recombinant osteocalcin fusion protein

#### Materials

10

Molecular biology reagents and enzymes were obtained from Pharmacia Biotech, Uppsala, Sweden or from New England Biolabs. Expression vector pGEX-3X was obtained from Pharmacia Uppsala, Sweden. *Escherichia coli* XL1-Blue strain (recA1, endA1, gyrA96, thi-1, hsdR17, supE44, relA1, lac, F' proAB, lacI<sup>q</sup>ZDM15, 15 Tn10 (tet<sup>r</sup>)) was used for the expression of the GST-rhOC fusion protein. L-broth culture medium contained 10 g/l Bacto<sup>®</sup> Tryptone (Difco laboratories, Michigan, USA), 5 g/l Bacto<sup>®</sup> Yeast extract (Difco) and 5 g/l NaCl, pH 7.4. Isopropyl-1-thio- $\beta$ -D-galactoside, IPTG (Sigma Chemical CO, USA) was used for induction. PBS buffer consisted of 150 mM NaCl, 16 mM Na<sub>2</sub>HPO<sub>4</sub>, 4 mM NaH<sub>2</sub>PO<sub>4</sub>, pH 7.3.

20

PMSF and reduced glutathione were obtained from Sigma and protease factor Xa, pfXa from New England Biolabs. Glutathione Sepharose<sup>®</sup> 4B column (bed volume 8 ml) was obtained from Pharmacia. The size separation of the proteins was done with SDS-PAGE 25 % gradient Phastgel and using Low molecular weight markers for standardization (Pharmacia). Bovine osteocalcin (bOC) was obtained from 25 Biodesign International, Kennebunkport, ME. A commercial anti-bOC Mab BD (Biodesign) was used as a primary antibody and a horseradish peroxidase linked anti-mouse immunoglobulin raised in sheep was used as a second antibody

(Amersham, Buckinghamshire, England). ECL Western blotting reagents (Amersham) were used for visualization according to manufacturer's suggestions.

5

## Equipment

Human osteocalcin oligomers and the oligomer primers designed for sequencing were synthesized on an Applied Biosystems (Foster City, CA) oligonucleotide synthesizer. Nucleic acid sequencing was done with T7 Sequencing Kit and Macrophor equipment from Pharmacia. The electroporation was done with Gene pulser (Bio-Rad, Richmond, CA). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was run with PhastSystem (Pharmacia). Matrix assisted laser desorption (MALDI-MS) mass spectrometer (LASERMAT<sup>R</sup>, Finnigan MAT Ltd., U.K.) was employed to obtain the mass of the peptides. A protein sequencer (Applied Biosystems model 477A) equipped with an on-line Applied Biosystems model 120A PTH amino acid analyzer was employed for the NH<sub>2</sub>-terminal amino acid analyses. Reverse phase chromatography was done using a C8 RP-300 column (4.6 x 100 mm) (Applied Biosystems). The proteins were electroblotted onto Hybond<sup>TM</sup>-C extra nitrocellulose membranes (Amersham) using PhastTransfer<sup>TM</sup> Semi-dry Transfer Kit (Pharmacia) according to PhastSystem<sup>TM</sup> manual.

25

## Plasmid construction

Synthetic human osteocalcin oligomers (Fig. 1A), each containing 88 nucleic acids (8 of them being complementary to each other) were hybridized at RT after phosphorylation of the ends. The single-stranded ends were filled by 1 U of Klenow

polymerase and 100  $\mu$ M of each deoxynucleotide (30 minutes incubation at 37 °C) to create a 160 base pair human osteocalcin insert, which contains a stop codon and a PstI restriction enzyme site at the 3' end of the gene (Fig. 1A). The blunt-ended insert was ligated in SmaI-digested, dephosphorylated prokaryotic expression vector, pGEX-3X (Fig. 1B). The recombinant plasmid was transformed into *E. coli* and the resulting vector was confirmed by restriction enzyme digestion and nucleic acid sequencing. All molecular biology protocols were according to Sambrook et al. Molecular Cloning, a Laboratory Manual, Second Edition, 1989, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

#### Expression of the GST-rhOC fusion protein

Transformed *E. coli* cells were grown at 37 °C in 250 ml of L-broth containing 100  $\mu$ g/ml ampicillin to an  $A_{600} = 0.5$  and then IPTG was added to a final concentration of 0.5 mM. Induced cells were grown for an additional 2 h and were collected by centrifugation, disrupted by sonication on ice in PBS buffer containing 2 mM PMSF, Sigma and 1 mM EDTA as protease inhibitors. After sonication, Triton-X-100 (1 % v/v) was added. The sonicate was clarified by centrifugation (10,000g, 20 min, 4 °C) and filtered through a 0.45  $\mu$ m filter before applying it to an equilibrated Glutathione Sepharose® 4B column according to manufacturer's suggestions.

#### Purification of the recombinant human osteocalcin

After concentration, the eluate containing the GST-rhOC fusion protein was incubated with pfxa in 20 mM Tris-HCl, 100 mM NaCl, 2 mM  $\text{CaCl}_2$ , pH 8.0, using a protease to substrate ratio of 0.5 % (w/w) for 30 min at RT to release the rhOC portion (Nagai and Thøgersen Nature 1984; 309:810-2). Then rhOC was separated from the mixture reverse phase chromatography using a C8 RP-300

column. The optimization of the rhOC purification has been described in detail by Käkönen et al. (1996).

### Verification of the protein products

5 The expression vector contained the entire sequence of the hOC gene fused in frame to the 3' end of the *Schistosoma japonicum* glutathione S-transferase gene (Smith and Johnson Gene 1988;. 67:31-40) as verified by nucleic acid sequencing. The resulting fusion protein contains three additional amino acids between the  
10 protease factor Xa cleavage site and the first amino terminal tyrosine of the hOC gene (Fig. 1B). The molecular mass of the reverse phase HPLC purified rhOC was 6068.1 as determined by mass spectrometry. This value is consistent with the predicted mass calculated from the amino acid sequence (6064.8, rhOC has a extension of three aminoacid residues (Gly-Ile-Pro) because of the of pfXa cleavage  
15 site in pGEX-3X plasmid (Fig. 1 A and B.). Purified GST-rhOC and rhOC were compared with hOC purified from bone and with bOC using SDS-PAGE and Western blotting analysis. The size of purified GST-rhOC (32 kDa) obtained by SDS-PAGE is in accordance with that expected from a fusion protein containing GST (26 kDa, Smith and Johnson Gene 1988;. 67:31-40) and rhOC (6068.1 Da).  
20 Purified rhOC migrates similarly both to hOC purified from human femurs and bOC on SDS-PAGE (Fig. 2A, lanes 3, 4 and 6, respectively). In Western blotting experiment, Mab BD binds to hOC and bOC (Fig. 2B, lanes 3 and 4, respectively) and also to the both recombinant forms, GST-rhOC and rhOC (Fig. 2B, lanes 5 and 6, respectively). A 64 kDa band is also observed from the fusion protein sample  
25 (Fig. 2B, lane 5) which probably indicates a dimeric form of GST-rhOC. Mab BD does not bind to GST or to any of the molecular weight markers (Fig. 2B, lanes 1 and 2, respectively).



## 2. Production of the osteocalcin monoclonal antibodies

### Materials and equipment

5 GST-rhOC used as an immunogen was produced as described (Käkönen et al. Prot Exp Purif 1996; 3:137-44). Bovine osteocalcin (bOC) was obtained from Biodesign International, Kennebunkport, ME. Freund's complete adjuvant (Fca) and Freund's incomplete adjuvant (Fia) were obtained from Sigma Immuno Chemicals, St Louis, MO. The Optimem-1 with glutamax-1, Dulbecco's Modified Eagle Medium  
10 (DMEM, 10 x liquid), L-glutamine, sodiumpyruvate (tissue culture tested), sodiumbicarbonate (tissue culture grade) and penicillin-streptomycin (P/S) solution were purchased from Gibco BRL, Life Technologies, Grand Island, NY, Hepes from Boehringer Mannheim, Germany and the fetal bovine serum from Hyclone, Logan, UT and were used as components in culture mediums. Reagents and  
15 equipment used for screening the hOC specific hybroma cell lines were obtained from Wallac Oy, Turku, Finland except the Europium-labeled hOC was prepared according to Hellman et al. (J Bone Miner Res 1996; 11:1165-75).

20 Pristane (2,6,10,14-tetramethyl pentadecan) used for the production of Mabs as ascitic fluid was obtained from Aldrich-Chemie, Steinhiem, Germany). Tecnomouse hollow-fiber bioreactor used for the large scale production of Mabs was obtained from Integra Biosciences AG, Wallisellen, Switzerland and Protein A agarose Affigel® for the purification of the Mabs was from Bio-Rad, Richmond, CA.

### 25 Immunization of the mice and screening of the hOC specific Mabs

The employing of recombinant OC fusion protein as an immunogen has been described earlier (Matikainen et al In "Animal cell technology: Developments towards the 21st century" 1995; pp. 475-9). Ten months old male Balb/c mouse was

intraperitoneally immunized with 413  $\mu$ g GST-rhOC antigen (corresponding to 75  $\mu$ g of rhOC portion) mixed with Fca. The mouse was boosted 15 weeks later with 358 of the same antigen (60  $\mu$ g of rhOC) mixed in Fia. The final booster dose, 110  $\mu$ g antigen (20  $\mu$ g of rhOC) in PBS was given i.p. after 8 weeks.

5

Bovine osteocalcin was coupled to keyhole limpet hemocyanin (KLH) as described (Young et al. Prostaglandines 1982; 23:603-13). Two three-month-old Balb/c male mice were i.p. immunized with 50  $\mu$ g of bOC-KLH antigen mixed with Fca. The mice were boosted with the same amount of antigen in Fia. The final booster dose, 10  $\mu$ g bOC-KLH in PBS, was given intravenously.

10

Three days after the final booster the splenocytes were fused to mouse myeloma cells SP 2/0 as described in more detail earlier (Lilja et al. Clin Chem 1991; 37:1618-25). The hybridomas were grown in Optimem-1 with glutamax-1 containing 20 % of fetal bovine serum. The hOC specific Mabs were screened with immunofluorometric assay (IFMA) using rabbit antimouse Ig microtitration wells and hOC labeled with Europium as described earlier (Matikainen 1995).

15

### Large scale production and purification of the Mabs

20

Before large scale production of Mabs the positive hybridomas were cloned at least twice by the limiting dilution method. Optimem-1 with glutamax-1 supplemented with 20 % of fetal bovine serum was used as culture medium. Cell lines 2H9F11F8 (2H9) and 6F9G4E10 (6F9) obtained from the GST-rhOC immunization and 3G8E1F11 (3G8), 1C4B1D7E7 (1C4) and 3H8H2D2A12F12 (3H8) obtained from bOC immunizations were selected for further characterization. The Mabs were produced as ascites fluid in Balb/c mice primed with pristane and in Tecnomouse hollow-fiber bioreactor. DMEM (1 x solution) supplemented with L-glutamine, Hepes, sodiumpyruvate, sodiumbicarbonate and P/S was used as a culture medium

25

in intracapillary circulation. Optimem-1 with glutamax-1 supplemented with 2.5 % fetal bovine serum was used as a harvesting medium in extracapillary space.

Produced Mabs were purified by Protein A agarose chromatography using Affigel<sup>®</sup> purification kit according to manufacturer's suggestions.

5

### 10 3. Epitope mapping, characterization of the Mabs and two-site assays

#### Materials

In the subclass determination of the Mabs, the streptavidin-coated microtiter plates  
15 were obtained from Wallac Oy and biotinylated rat antimouse Ig subclass specific  
Mabs from Serotec, Oxford, England. For epitope mapping the synthetic osteocalcin  
peptide 7-19 containing Glu at residue 17 was purchased from Bachem, Switzerland  
and bovine osteocalcin (bOC) was obtained from Biodesign International,  
Kennebunkport, ME. Osteocalcin from human femurs was purified by modifying a  
20 previously described method (Gundberg et al. Meth Enzymol 1984; 107:516-544) as  
explained in detail by Hellman et al. (1996). Also the carboxypeptidase Y digestion,  
trypsin digestion, alkylation and decarboxylation of hOC has been described earlier  
(Hellman et al. 1996). The detailed characterization of the hOC and its  
modifications is described by Hellman et al. (1996). The recombinant forms of  
25 osteocalcin were produced as explained in section 1. The production and  
purification of a truncated form of rhOC (del. rhOC) (lacking 10 COOH-terminal  
amino acid residues) from a gene carrying a stop mutation in the structural region  
was performed under similar conditions. Both rhOC and del rhOC have an

extension of three amino acid residues in their NH<sub>2</sub> termini; in addition, they lack the  $\gamma$ -carboxylation characteristic of hOC isolated from bone.

Reagents for biotinylation, biotin isothiocyanate (BITC) and labeling, europium(III) chelate of 4-[2(-4-isothiocyanatophenyl)ethynyl]-2,6-bis{[N,N-bis(carboxymethyl)amino]methyl}pyridine (Takalo et al. *Helv Chim Acta* 1993; 76:877-83) were from Wallac Oy. Streptavidin coated microtiter plates, Delfia<sup>®</sup> Buffer, Delfia<sup>®</sup> Wash Solution, Delfia<sup>®</sup> Enhancement Solution and Delfia<sup>®</sup> Research Fluorometer, Model 1234 used in IFMA measurements were obtained from Wallac Oy. Reagents and equipment used in the immunoassays were similar throughout the study.

#### Characterization of the Mabs

- 15 Labeling of the peptides for subclass determination and epitope mapping was done according to Hellman et al. 1996. The Mabs 6F9, 3G8, 1C4 and 3H8 belonged to subclass IgG1 and the Mab 2H9 to subclass IgG2a as determined according to Matikainen et al., 1995.
- 20 Mabs were characterized for their binding to Eu-labeled intact hOC, bOC and tryptic or synthetic peptides as described (Hellman et al. 1996). The antibodies 1C4 and 3H8 obtained by immunization with bOC conjugated to KLH recognized the tryptic 20-43 fragment. For Mab 3G8, also obtained from bOC immunizations, no specific binding site could be located using labeled peptides. Also, labeling of intact
- 25 bOC and hOC abolished their immunoreactivity with 3G8, suggesting either that intact Tyr (1) is needed for efficient binding or that the Eu-chelate causes steric hindrance. Unlabeled intact hOC or bOC were, however, easily recognized by this antibody in a two-site format with Mab 2H9. Mab 6F9 recognized the tryptic 1-19 and synthetic 7-19 peptides. Mab 2H9 recognized the tryptic 20-43 peptide.

Summary of the Mabs in Table 1. According to information obtained an epitope map was created (Fig.3).

Table 1. Characterization of Mabs against

Hybridoma clone	Immunogen	Immunoglobulin class H-chain <sup>a</sup>	Eu-labeled OC forms recognized <sup>b</sup>					
			Eu-hOC	Eu hOC 1-19	Eu-hOC 7-19	Eu-hOC 15-31	Eu-hOC 20-43	Eu-bOC
2H9	rGST-hOC	IgG2a	+	-	-	+	+	+
3G8	bOC-KLH	IgG1	+ <sup>c</sup>	-	-	-	-	+ <sup>c</sup>
3H8	bOC-KLH	IgG1	+	-	-	+	+	+
1C4	bOC-KLH	IgG1	+	-	-	+	+	+
6F9	rGST-hOC	IgG1	+	+	+	+	-	-

<sup>a</sup> All light chains.

<sup>b</sup> Measured according to Hellman et al. 1996 c Mab 3G8 recognizes unlabeled hOC and bOC when tested with

<sup>c</sup> Mab 3G8 recognizes unlabeled hOC and bOC when tested with two-site

## Biotinylation and Eu labeling of the Mabs

In order to create two-site combination assays the Mabs 3G8, 2H9 and 6F9 were biotinylated with BITC and the Mabs 2H9, 6F9, 1C4 and 3H8 were labeled with europium(III) chelate in reaction conditions previously described (Hellman et al, 1996). The two-site immunoassay utilized time-resolved fluorometry using lanthanide chelate labels, like europium, as a detection system (Soini and Lövgren CRC Crit Rev Anal Chem. 1987; 18:105-53).

## Characterization of the two-site assays

Four of the two-site combinations were validated in more detail by determination of the crossreactivities to the alkylated hOC, decarboxylated hOC, carboxypeptidase Y-digested hOC, recombinant hOC and truncated recombinant hOC. According to

information obtained by crossreactivity determination and the epitope mapping the assay # 2 (bio-3G8/Eu-2H9) was considered specific for the full length, intact hOC molecule. The assays # 4 (bio-2H9/Eu-6F9), #7 (bio-6F9/Eu-1C4) and #9 (bio-6F9/Eu-3H8) were able to detect the full length hOC and also the large NH<sub>2</sub>-terminal fragment. Assay #4 measured both  $\gamma$ -carboxylated and fully decarboxylated form of hOC. The #9 and #7 assays distinctively preferred the carboxylated form of hOC. Determination of the affinity constants of labeled Mabs were done according to Hellman et al. 1996 using Scatchard analysis (Scatchard, Ann NY Acad Sci 1949; 51:660-72). Characteristics of the assays are summarized in Table 2.

Table 2. Characteristics of the two-site IFMAs of

Combination number	Capture Mab	Tracer Mab	K <sub>a</sub> (x 10 <sup>6</sup> L/mol <sup>a</sup> of tracer Mab in		
			AB	+ 5 mM EDTA	+ 25 mM Ca
2	3G8	2H9	3.30	3.40	4.20
4	2H9	6F9	0.7	0.83	0.42
7	6F9	1C4	0.13	0.11	0.07
9	6F9	3H8	0.68	0.64	0.2

Combination number	Capture Mab	Tracer Mab	Crossreactivities in percent (w/w) <sup>b</sup>					
			hOC	dec. hOC	rhOC	CPY hOC	del. rhOC	alkvl. hOC
2	3G8	2H9	100	64	69	9	1	76
4	2H9	6F9	100	46	44	150	65	75
7	6F9	1C4	100	19	6	169	18	6
9	6F9	3H8	100	8	7	156	6	3

<sup>a</sup> Affinities determined according to Scatchard as described by

<sup>b</sup> Measured as described by Hellman et

In addition to two-site non-competitive assays, the hOC specific antibodies could be utilized in competitive assays as a capture antibody. In competitive assay hOC fragments in urine compete with the Eu-labeled hOC for binding to the limited

number of capture Mabs. With Mabs 2H9, 1C4 and 3H8 also Eu-labeled hOC could be used due to crossreactivities explained in Table 1.

#### 5 4. Optimized assay procedures

##### Materials and equipment

The employed Mabs have been characterized in the previous section. In addition to  
10 Mabs produced in hybridoma cell culture, also recombinant antibody fragments  
could be used in the assay concept. hOC and CPYhOC (Carboxy-peptidase Y  
digested hOC) used for the standardization of the assays were produced as  
explained in section 3. DTPA (diethylenetriaminepentaaceticacid) -treated BSA in  
TSA-buffer (50 mM Tris-HCl, 150 mM NaCl, 15 mM NaN<sub>3</sub>, pH 7.75) used as a  
15 diluent in standardization was obtained from Wallac Oy. Materials and equipment  
used in the OC IFMAs have been listed in the section 3.

##### All-in-one assays optimized for serum samples

20 10 µl of samples and standards were pipetted streptavidin coated microtiter plates.  
The calibration curve was prepared using purified hOC in 7.5 % (w/v) DTPA-  
treated BSA in TSA buffer as a standard covering the range from 0.5 to 80 ng/ml.  
Then a mixture of biotinylated and Eu labeled Mabs in 50 µl of Delfia<sup>®</sup> Buffer was  
added to the wells. The amount of capture or tracer Mab was 200 ng/well except  
25 100 ng/well of tracer Mabs were used in assays #2 and #9. 5 mM EDTA was added  
into Delfia<sup>®</sup> Buffer in assays #4, #7 and #9. The plates were shaken for 2 h at RT  
followed by washing six times with Delfia<sup>®</sup> Wash Solution. To detect the Eu  
fluorescence, 200µl of Delfia<sup>®</sup> Enhancement solution per well was added. Prior to

the measurement with the Delfia<sup>®</sup> Research Fluorometer the plates were shaken 30 min at RT.

The lower limit of the detection of the different assays were determined based on two standard deviations of the background signal produced by the standard diluent and was under 0.1 µg/L for each assay. The developed IFMAs showed a linear response of over four orders of magnitude and were highly reproducible.

#### Osteocalcin assays optimized for urine samples

The calibration curve for assay #4 was prepared using purified hOC purified hOC in 7.5 % (w/v) DTPA-treated BSA in TSA buffer as a standard covering the range from 0.05 to 16 ng/ml. Carboxy-peptidase Y digested hOC (CPY hOC) in the same diluent covering the range from 0.05 to 16 ng/ml was used for standardization for the assays #7 and #9.

First, 400 ng of biotinylated capture Mab in 50 µl of Delfia<sup>®</sup> Buffer was pipetted to the streptavidin well. After 30 minutes shaking at room temperature the excess capture Mab was removed by two washings using Delfia<sup>®</sup> Wash Solution. Before the adding labeled tracer Mab in 50µl Delfia<sup>®</sup> Buffer, the standard or sample was pipetted in 10 µl volume. 100 ng of labeled tracer was used except in assay #7 where 200 ng/well of Eu-1C4 was used. After two hours shaking at room temperature, the wells were washed six times and 200µl of Delfia<sup>®</sup> Enhancement solution per well was added. Prior to the fluorescence measurement, the plate was shaken 30 minutes at room temperature. The assays were highly linear and reproducible. The lowest detection limits were under 0.1 µg/L.



## 5. Isolation and characterization of urine osteocalcin fragments

### Materials and equipment

- 5 Carboxy-peptidase Y digested hOC (CPY hOC) used for standardization of the urine IFMAs was produced as explained in section 3. Immunoaffinity chromatography coupled with purified 6F9Mab (section 2) using Affi-Gel Hz Immunoaffinity kit from Bio-Rad, a C-18 solid phase extraction cartridge (Millipore) and a C-4 reverse phase HPLC column (Vydac, Hesperia, CA, U.S.A.)  
10 were used for the isolation of uhOC fragments. Matrix assisted laser desorption MALDI-TOF mass spectrometer (LASERMAT<sup>R</sup>, Thermo Bioanalysis Ltd., U.K.) was employed for mass determinations and a protein sequencer (Applied Biosystems model 477A) equipped with an on-line Applied Biosystems model 120A PTH amino acid analyzer was used for the NH<sub>2</sub>-terminal amino acid sequence  
15 analyses.

### Sample collection and uhOC IFMA

- Urine pool was collected in the morning from one healthy male volunteer aged 13  
20 years and stored at +4 °C. Within three hours the pool was aliquoted and frozen at -70 °C. Later it was stored at -20 °C. Urine pool was thawed, centrifuged and filtrated before subjected to any isolation steps.

- Immunoreactive uhOC in both urine pool and different steps of isolation process  
25 was measured with a two-site immunoassay recognizing, not only the intact hOC, but also the N-terminal mid-fragment of hOC (amino acid residues 1 - 43) (Fig. 3). The assay used monoclonal antibodies (Mabs) 6F9 and 1C4 as a capture and tracer Mab, respectively (combination #7). The calibration curve was prepared using carboxy-peptidase Y digested hOC (CPY hOC) as a standard. The amount of

immunoreactive uhOC in puberty urine pool was 100 ng/ml. Also the assays #9 (Mab combination 6F9/3H8) and #4 (Mab combination 2H9/6F9) were utilized to determine the immunoreactive fragments as described in section 4.

5

### Isolation of osteocalcin fragments

First, immunoreactive osteocalcin fragments from puberty urine pool were adsorbed by immunoaffinity chromatography. The gel matrix was covalently coupled with hOC Mab 6F9 recognizing an N-terminal epitope (Fig. 3). After adsorption the bound fragments were eluted by 0.1 M acetic acid and adsorbed onto a C-18 solid phase extraction cartridge, again eluted with 80 % acetonitrile (AcN) and evaporated. In the immunoaffinity chromatography, over 90 % of the immunoreactive uhOC was adsorbed onto the 6F9 coupled gel. In the elution step (including adsorption steps and washings of the gel) 10 % of the adsorbed uhOC was eluted. To improve the yield more urine was applied onto the affinity column and then the eluent was recycled 5 hours through the affinity column attached to two C-18 solid phase extraction cartridges all connected to each others in series. After evaporation the C-18 solid phase eluent contained at least 2 mg/ml of immunoreactive uhOC as measured by the urine hOC assay utilizing Mab combination #7.

Next, the sample containing the immunoreactive fragments was applied onto a Vydac C-4 (2.1 mm x 150 mm) reverse phase HPLC column, eluted with an acetonitrile gradient (Fig. 4) and the peak fractions detected at 276 nm were collected manually. The sample contained multiple immunoreactive fragments of OC, which eluted between 70 min (35% AcN), and 82 min (48% AcN) (Fig.4). Fractions containing 1.4 - 19.5 µg/ml of immunoreactive uhOC were subjected to further analysis.

### Characterization of osteocalcin fragments

HPLC fractions were analyzed by the two-site immunoassays #7, #9 and #4 as before and fractions containing immunoreactive uhOC fragments were subjected to MALDI-TOF mass spectrometry and N-terminal amino acid sequencing. The molecular masses of the prominent ions in mass spectrometry were 2778, 2814, 2930 and 3005. Fractions 44 (M=2814) and 46 (M=2930) contained enough material for the N-terminal sequence analysis. The sequence obtained from fraction 44 matches with hOC starting from residue Gly(7). Taking into account the experimental mass 2814, the fragment spans residues 7-30, with  $\gamma$ -carboxylated residues at positions 17, 21 and 24 giving a calculated mass of 2812 (Fig. 5 A).  $\gamma$ -carboxylation of the Glu residues is further supported by the fact that  $\gamma$ -carboxylated Glu residues are known not to give signal using the sequencing technique in question (Cairns et al. (1991) Anal Biochem. 199, 93-97). Fraction 46 was subjected to trypsin digestion to demonstrate that the fragment can be cleaved as expected (after Arg residue). In addition, the determined N-terminal sequence matches with hOC starting from residue Leu(6). The determined mass of the N-terminal part of the fragment cleaved with trypsin was 1566 and in accordance with the expected mass mass (1565 with  $\gamma$ -carboxylated Glu 17). According to the determined mass of fraction 46 before trypsin cleavage (2930, Fig 5B) the fragment spans residues 6-30 of hOC with three  $\gamma$ -carboxylated residues as above (calculated mass 2925). The ion species with masses 2778 (Fig. 5 C) and 3005 (Fig. 5 D) represent close structural variants of the same hOC region, based on immunoreactivity, chromatographic behaviour and molecular mass. Such structural variability can be caused by partial lack of  $\gamma$ -carboxylation or additional 1-2 residues, and/or combinations of both. The characteristics of the fragments have been described in figure 5 E. In addition to immunoassay #7, also assay #9 recognize effectively these forms of urine osteocalcin. Epitope of #4 differs slightly from

epitope recognized by the combination #7 and #9 because the combination could not recognize the 7-30 fragment but could detect the fragment which mass was 3005. Urine may contain shorter hOC fragments which remain to be characterized.

5

## **6. Determination of osteocalcin concentrations in serum and urine panels**

### **Materials and equipment**

10 FSH concentration of serum samples was measured by Delfia<sup>®</sup> hFSH assay (Wallac, Turku, Finland). The creatinine concentration in urine samples was measured using AU OLYMPUS 510 equipment according to manufacturer's protocols. The protocols of the shOC and uhOC assays have been described in section 5.

### **15 Subjects and sample collection**

Clinical evaluation of the assays was performed with serum and urine samples collected between 8 and 11 o'clock in the morning from 58 pre-, 9 peri- and 20 postmenopausal women, 12 postmenopausal women with hormone replacement therapy (HRT) and 16 pubertal girls. In addition to female panel, also a male panel was collected consisting of 46 adult men and 19 pubertal boys. The serum samples were allowed to clot for 30 min. at room temperature before centrifuging and then immediately aliquoted and stored at -70 °C. Collected urine samples were first frozen at -70 °C and then stored at -20 °C. The women were divided into pre-, peri- and postmenopausal groups according to menstrual status and FSH concentration in serum. The postmenopausal group was further classified into subjects with or without hormone replacement therapy (HRT).

### hOC concentrations in serum and urine samples

Serum samples were measured with intact hOC assay specific for full-length hOC (#2), with total hOC assay recognizing not only the intact hOC, but also the N-terminal midfragment of hOC (#4) and with two assays dependent on the degree of  $\gamma$ -carboxylation of the glutamic acids in hOC (#7 and #9). The urine samples were measured with two  $\gamma$ -carboxylation dependent assay (#7 and #9) and also with assay #4. The urine osteocalcin values used for analysis have been corrected for creatinine.

### shOC and uhOC in pubertal subjects compared to adult subjects

In women the hOC values observed in serum samples were six to eight fold higher in pubertal girls than in adults. In urine, the hOC concentrations were twelve to sixteen fold higher when comparing the pubertal group to the adults. (Fig. 6.). In men the increase was five fold in serum and eight to eleven fold in urine. Although, the hOC concentration level observed by the assay # 4 is approximately five fold lower than the level observed by assays # 7 or # 9, the concentrations differ significantly between examined groups. All increases were highly significant ( $p < 0.001$ ). The accurate values have been summarized in the Table 3.

**Table 3.** The difference in hOC concentrations between pubertal and adult males and females.

group	shOC #2	shOC #4	shOC #7	shOC #9	uhOC #4	uhOC #7	uhOC #9
female	6.3	7.8	6.9	6.2	16.5	12.3	12.5
male	4.9	4.7	4.8	4.9	10.8	8.2	8.3

### shOC and uhOC in different menopausal groups

The statistically significant increase in hOC concentrations in serum was observed in menopause (40 to 48 %). Interestingly, in urine samples the increase in hOC concentration was as high as 75 % and 79 % as measured with assays #7 and #9, respectively ( $p < 0.001$ ). The increase of urine hOC between the pre- and postmenopausal groups was even higher when measured with assay #4 (125 %,  $p < 0.001$ ). hOC concentrations in postmenopausal subjects on HRT decreased to concentrations indistinguishable from the premenopausal group with every hOC assay in both serum and urine specimens. Statistically significant decreases (30 to 46 %) in serum concentrations were seen depending on the assay used. However, the observed decrease in urine samples was over 50 %. (Fig. 7 A and B.). Although, the hOC concentration level observed by the assay # 4 is approximately five fold lower than the level observed by assays # 7 or # 9, the concentrations differ significantly between examined groups. The discriminatory power of each assay has been summarized in Table 4.

**Table 4.** Percentual differences and statistical significancies between menopausal groups as measured by hOC IFMAs in serum and urine samples.

	shOC #2	shOC #4	shOC #7	shOC #9	uhOC #4	uhOC #7	uhOC #9
Increase in menopause (%)	42	48	43	40	125	75	79
p-value	0.0008	<0.0001	<0.0001	<0.0001	<0.0001	<0.0001	<0.0001
Decrease in HRT (%)	46	30	35	33	57	51	57
p-value	0.0021	0.0161	0.0065	0.0086	0.0352	0.0133	0.0074

Although the assays definitely detected different forms of circulating hOC, their performance in measuring the serum panel was almost identical. The IFMAs were

even more effective in discriminating postmenopausal group from premenopausal group and also postmenopausal group under HRT from postmenopausal control group when measured in urine samples.

- 5 The serum hOC assays correlated well with each other. On the contrary, differences between urine assays were observed. As explained in section 5 the assay #4 recognizes a slightly different fragment in urine than assays #7 and #9. This might explain the weaker correlation between the assays #4 and #7 ( $r = 0.843$ , Fig. 8 A) than between assays #7 and #9 ( $r = 0.976$ , Fig. 8B) as measured in the urine  
10 samples. When comparing the hOC values in urine and serum samples the correlation was remarkably lower although measured by the same Mab combination. Correlations between urine and serum samples in assay #7 ( $r = 0.625$ ) and assay #4 ( $r = 0.427$ ) are illustrated in Fig. 8 C and D, respectively. All the correlations were significant ( $p < 0.001$ ) and have been summarized in Table 5.

15

Table 5. Correlations between the hOC assays as measured in serum and urine samples from adult females. All the correlations are significant ( $p < 0.001$ ).

	shOC #2	shOC #4	shOC #7	shOC #9	uhOC #4/creat	uhOC #7/creat	uhOC #9/creat
shOC #2	1.000	.823	.867	.870	.422	.521	.558
shOC #4	.823	1.000	.932	.929	.427	.555	.572
shOC #7	.867	.932	1.000	.989	.504	.625	.648
shOC #9	.870	.929	.989	1.000	.519	.653	.671
uhOC #4/creat	.422	.427	.504	.519	1.000	.843	.824
uhOC #7/creat	.521	.555	.625	.653	.843	1.000	.976
uhOC #9/creat	.558	.572	.648	.671	.824	.976	1.000

20

It will be appreciated that the methods of the present invention can be incorporated in the form of a variety of embodiments, only a few of which are disclosed herein. It will be apparent for the specialist in the field that other embodiments exist and do not depart from the spirit of the invention. Thus, the described embodiments are  
25 illustrative and should not be construed as restrictive.

## CLAIMS

1. An isolated osteocalcin fragment derived from human urine, said fragment  
characterized in that at least one of the glutamic acids in the position 17, 21 and 24  
 5 of the amino acid sequence

6    7

Tyr-Leu-Tyr-Gln-Trp-Leu-Gly-Ala-

10    Pro-Val-Pro-Tyr-Pro-Asp-Pro-Leu-

17                      21                      24

Glu-Pro-Arg-Arg-Glu-Val-Cys-Glu-Leu-

30

15    Asn-Pro-Asp-Cys-Asp-Glu-Leu-Ala-

Asp-His-Ile-Gly-Phe-Gln-Glu-Ala-

20    Tyr-Arg-Arg-Phe-Tyr-Gly-Pro-Val

is gamma-carboxylated.

2. The fragment according to claim 1 characterized in that the fragment spans from  
 25 the amino acid in position 7 to the amino acid in position 30 of the amino acid  
 sequence described in claim 1, and that all three glutamic acids in the positions 17,  
 21 and 24 of said sequence are gamma-carboxylated.
3. The fragment according to claim 1 characterized in that the fragment spans from  
 30 the amino acid in position 6 to the amino acid in position 30 of the amino acid  
 sequence described in claim 1, and that all three glutamic acids in the positions 17,  
 21 and 24 of said sequence are gamma-carboxylated.



4. A monoclonal antibody or recombinant antibody fragment characterized by the capability of binding the human gamma-carboxylated osteocalcin fragment according to claim 1, 2 or 3.

5 5. The monoclonal antibody or recombinant antibody fragment according to claim 4 characterized by the specificity to epitopes that have been identified on the gamma-carboxylated fragment of osteocalcin, wherein said fragment spans either

i) from the amino acid in position 7 to the amino acid in position 30, or

ii) from the amino acid in position 6 to the amino acid in position 30

10 of the amino acid sequence described in claim 1, and that all three glutamic acids in the positions 17, 21 and 24 of said sequence are gamma-carboxylated.

6. A cell line producing the monoclonal antibody according to claim 4 or 5.

15 7. An immunoassay for quantitative determination of a gamma-carboxylated osteocalcin fragment according to claim 1 characterized in that a sample containing said fragment is exposed to a monoclonal antibody or recombinant antibody fragment which binds said gamma-carboxylated osteocalcin fragment.

20 8. The immunoassay according to claim 7 characterized by employing a monoclonal antibody or recombinant antibody fragment specific to epitopes that have been identified on the gamma-carboxylated fragment of osteocalcin, wherein said fragment spans either

i) from the amino acid in position 7 to the amino acid in position 30, or

25 ii) from the amino acid in position 6 to the amino acid in position 30

of the amino acid sequence described in claim 1, and that all three glutamic acids in the positions 17, 21 and 24 of said sequence are gamma-carboxylated.

9. The immunoassay according to claim 7 or 8 characterized in that the immunoassay is non-competitive employing at least two different monoclonal antibodies or recombinant antibody fragments.

5 10. The immunoassay according to claim 9 characterized in that the non-competitive immunoassay is carried out in either a one-step or a two-step incubation procedure.

11. The immunoassay according to claim 9 characterized in that the two monoclonal antibodies employed are the antibodies 2H9 and 6F9 that recognize the C-terminal  
10 and N-terminal epitopes on the fragment which was determined to be 3005.

12. The immunoassay according to claim 9 characterized in that the two monoclonal antibodies employed are the antibodies 6F9 and 1C4 that recognize the N-terminal and the C-terminal epitopes on the measured osteocalcin fragments (6-30 or 7-30).  
15

13. The immunoassay according to claim 9 characterized in that the two monoclonal antibodies employed are the antibodies 6F9 and 3H8 that recognize the N-terminal and the C-terminal epitopes on the measured osteocalcin fragments (6-30 or 7-30).

20 14. A method for the measurement of the rate of bone turnover (formation and/or resorption) and/or for the investigation of metabolic bone disorders in an individual, characterized by quantitative determination of a fragment according to any of the claims 1 to 3.

25 15. The method according to claim 14 characterized in that an immunoassay according to any of the claims 7 - 13 is employed.

1/13

5' Tyr Leu Tyr Gln Trp Leu Gly Ala Pro Val Pro  
 TAC CTG TAT CAA TGG CTG GGA GCC CCA GTC CCC  
 Tyr Pro Asp Pro Leu Glu Pro Arg Arg Glu Val  
 TAC CCG GAT CCC CTG GAG CCC AGG AGG GAG GTG  
 Cys Glu Leu Asn Pro Asp Cys Asp Glu Leu Ala  
 TGT GAG CTC AAT CCG GAC TGT GAC GAG TTG GCT  
 Asp His Ile Gly Phe Gln Glu Ala Tyr Arg Arg  
 GAC CAC ATC GGC TTT CAG GAG GCC TAT CGG CGC  
 Phe Tyr Gly Pro Val stop PstI  
 TTC TAC GGC CCG GTC TAA CTG CAG ATGC 3'

FIG. 1A




FIG. 1B

2/13




FIG. 2B




FIG. 2A




FIG.3

4/13




FIG. 4

5/13





FIG. 5A

6/13

FIG. 5B





7/13






FIG. 5C

8/13

FIG. 5D



9/13




fraction number	fragment length	determined mass	amino acid sequence	$\gamma$ -carboxylated glutamic acid residues
43	N. D.	2778	not determined	1 -3 residues
44	7-30	2814	GAPVPYPDPLGlaPRRGlaVCGlaLNPD	17, 21 and 24
46	6-30	2930	LGAPVPYPDPLGlaPRRGlaVCGlaLNPD	17, 21 and 24
47	N.D.	3005	not determined	1 -3 residues

<sup>1</sup> Tyr -Leu-Tyr-Gln-Trp-Leu-<sup>6</sup> <sup>7</sup> *Gly-Ala-Pro-Val-Pro-Tyr-Pro-Asp-Pro-Leu-*  
<sup>30</sup> *Gla-Pro-Arg-Arg-Gla-Val-Cys-Gla-Leu-Asn-Pro-Asp-Cys-Asp-Glu-Leu-*  
<sup>49</sup> Ala-Asp-His-Ile-Gly-Phe-Gln-Glu-Ala-Tyr-Arg-Arg-Phe-Tyr-Gly-Pro-Val

FIG. 5E

10/13



11/13




FIG. 7A






FIG. 7B

12/13



13/13




FIG. 8C




FIG. 8D

# INTERNATIONAL SEARCH REPORT

1

International application No.

PCT/FI 98/00550

## A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C07K 14/47, C07K 16/18, G01N 33/68  
According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C07K, G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

REG, CAPLUS, WPI

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	EP 0834740 A1 (EISAI CO., LTD.), 8 April 1998 (08.04.98), see claims --	1,4,6-7
X	EP 0557663 A1 (DELMAS, PIERRE, DR.), 1 Sept 1993 (01.09.93) --	1,4,6-7
A	Peptide Research, Volume 7, No 4, 1994, M. Nakao et al, "Synthesis of Human Osteocalcins: gamma-Carboxyglutamic Acid at Position 17 is Essential for a Calcium-Dependent Conformational Transition" page 171 - page 174 --	1-13

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

\* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

26 November 1998

02 -12- 1998

Name and mailing address of the ISA/  
Swedish Patent Office  
Box 5055, S-102 42 STOCKHOLM  
Facsimile No. +46 8 666 02 86

Authorized officer

Carolina Gómez Lagerlöf  
Telephone No. +46 8 782 25 00



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 98/00550

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>Journal of Bone and Mineral Research, Volume 11, No 8, 1996, Jukka Hellman et al, "Epitope Mapping of Nine Monoclonal Antibodies Against Osteocalcin: Combinations into Two-Site Assays Affect Both Assay Specificity and Sample Stability" page 1165 - page 1175</p> <p>-- -----</p>	1-13

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 98/00550

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 14-15  
because they relate to subject matter not required to be searched by this Authority, namely:  
See PCT Rule 39.1(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest.

☐

No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

03/11/98

International application No.  
PCT/FI 98/00550

Patent document cited in search report.			Publication date	Patent family member(s)		Publication date
EP	0834740	A1	08/04/98	JP	9329600 A	22/12/97
				WO	9738309 A	16/10/97
-----						
EP	0557663	A1	01/09/93	SE	0557663 T3	
				AT	152525 T	15/05/97
				DE	69219451 D,T	23/10/97
				ES	2103906 T	01/10/97
				JP	6078788 A	22/03/94
-----						